

RISE Scholarship Program Charter

1. Purpose

- 1.1. RISE Scholarship Program, established by Mirum Pharmaceuticals Canada Inc., provides financial support to Canadian students affected by cholestatic liver disease, including siblings of individuals with the condition.
- 1.2. The program seeks to empower youth by supporting their pursuit of post-secondary education, while reinforcing Mirum's commitment to patients, families, and the rare liver disease community.

2. Scope

- 2.1. Scholarships will be awarded to eligible students enrolled in or accepted to a recognized Canadian post-secondary institution.
- 2.2. Each scholarship award will be valued at \$3,000 CAD, with up to five (5) awards granted, subject to funding approval.
- 2.3. Funds are intended for tuition, books, and other educational expenses.

3. Governance

- 3.1. Program Owner: Mirum Pharmaceuticals Canada
- 3.2. Selection Committee:
 - 3.2.1. Three (3) external Healthcare Professionals in relevant healthcare or academic fields.
 - 3.2.2. One (1) optional patient advocacy representative.
 - 3.2.3. One (1) Mirum observer (non-voting role).
 - 3.2.4. Conflict of Interest: All committee members must complete a COI declaration before application review.
- 3.3. Decision-making: Selection Committee decisions are independent and final.

4. Eligibility

- 4.1. Applicants must:
 - 4.1.1. Be Canadian citizens or permanent residents.
 - 4.1.2. Be diagnosed with cholestatic liver disease (e.g., Alagille syndrome, PFIC),
 - 4.1.2.1. or be the sibling of an affected individual.
 - 4.1.3. Be enrolled in or accepted to a recognized Canadian post-secondary institution.
 - 4.1.4. Have not received the RISE Scholarship previously. Previous award recipients are ineligible to apply for the award. Award recipients are only eligible to receive one award lifetime.
- 4.2. Applicants must submit:
 - 4.2.1. A personal essay describing the impact of cholestatic liver disease on their life and how they have demonstrated resilience.
 - 4.2.2. Two (2) letters of recommendation.
- 4.3. Employees, contractors, and immediate family members of Mirum and program vendors are **ineligible** for this award.

RISE Scholarship Program Charter

5. Application & Review

- 5.1. Applications must be submitted through the designated bilingual website (mirumcanadarisescholarship.ca) by the annual deadline (May 31, 2026, at 11:59 pm PST for the inaugural program).
- 5.2. Applications will be reviewed for any potential conflicts of interest; Selection Committee members will recuse themselves from judging any applications with a conflict of interest.
- 5.3. Submissions will be anonymized before distribution to the Selection Committee.
- 5.4. Applications will be assessed according to the published criteria, which may be adjusted with Mirum approval.
- 5.5. Final decisions will be communicated directly to recipients by phone and email.

6. Award Details

- 6.1. Each recipient will be awarded \$3,000 CAD.
- 6.2. Recipients consent to their details being included in RISE Scholarship Program materials.
- 6.3. Proof of enrolment will be collected and archived before releasing funds.
- 6.4. Funds to be disbursed directly to the award recipient.

7. Compliance & Safeguards

- 7.1. The program is independent of product promotion. No reference to Mirum products may appear in scholarship materials.
- 7.2. The program will comply with:
 - 7.2.1. Health Canada requirements.
 - 7.2.2. The Innovative Medicines Canada (IMC) Code of Ethical Practices.
 - 7.2.3. Federal and provincial privacy laws (PIPEDA).
- 7.3. Applicant information will be securely stored for a period not exceeding 5 years and then destroyed in accordance with Mirum's privacy policies.

8. Reporting & Evaluation

- 8.1. A Program Report will summarize applications, recipients, and impact (in aggregate, anonymized form) for each award period.
- 8.2. COI forms, adjudication notes, and award records will be archived in an Audit File.
- 8.3. The program will be reviewed following each award period by Mirum Pharmaceuticals Canada to ensure continued alignment with objectives and regulatory requirements.

9. Amendment & Termination

- 9.1. Mirum Pharmaceuticals Canada reserves the right to revise program policies or discontinue the program at any time, subject to approval from legal and compliance departments.